Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest

Pharmaceutical Research

Volumn 25, Issue 10, 2008, Pages 2272-2282

  Zheng, Hong ^a,b   Hu, Wei ^a   Yu, Dongfang ^a   Shen, De Yu ^a   Fu, Siqing ^a   Kavanagh, John J ^a   Wei, I Chien ^a   Yang, David J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

CDDP; CDDP analogue; Drug resistance; Ovarian cancer

Indexed keywords

ASPARTIC ACID; CASPASE 3; CHONDROITIN; CISPLATIN; CYCLIN A; DIAMMINE DICARBOXYLIC ACID PLATINUM; DICARBOXYLIC ACID DERIVATIVE; P21 ACTIVATED KINASE; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPARTIC ACID; CELL PROLIFERATION; CHONDROITIN; CISPLATIN; CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; S PHASE;

EID: 51649129978     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9621-4     Document Type: Article

References (35)

1. A. Jemal L. X. Clegg E. Ward L. A. Ries X. Wu P. M. Jamison P. A. Wingo H. L. Howe R. N. Anderson B. K. Edwards 2004 Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival Cancer 101 3 27
2. J. J. Kavanagh, S. Pecoreli, A. Dipertrillo, and N. Einhorn. Chemotherapy in advanced ovarian cancer. Blackwell Scientific, Cambrige, MA, 1998.
3. W. P. McGuire W. J. Hoskins M. F. Brady P. R. Kucera E. E. Partridge K. Y. Look D. L. Clarke-Pearson M. Davidson 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments] N Engl J Med. 334 1 6
4. M. J. Piccart H. Lamb J. B. Vermorken 2001 Current and future potential roles of the platinum drugs in the treatment of ovarian cancer Ann Oncol. 12 1195 1203
5. J. T. Thigpen 2000 Chemotherapy for advanced ovarian cancer: overview of randomized trials Semin Oncol. 27 11 16
6. G. Giaccone 2000 Clinical perspectives on platinum resistance Drugs. 59 Suppl 4 9 17 discussion 37-18
7. S. Manic L. Gatti N. Carenini G. Fumagalli F. Zunino P. Perego 2003 Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair Curr Cancer Drug Targets. 3 21 29
8. C. Balch T. H. Huang R. Brown K. P. Nephew 2004 The epigenetics of ovarian cancer drug resistance and resensitization Am J Obstet Gynecol. 191 1552 1572
9. W. P. McGuire R. F. Ozols 1998 Chemotherapy of advanced ovarian cancer Semin Oncol. 25 340 348
10. W. P. McGuire 3rd M. Markman 2003 Primary ovarian cancer chemotherapy: current standards of care Br J Cancer. 89 Suppl 3 S3 8
11. M. A. Fuertes J. Castilla C. Alonso J. M. Perez 2002 Novel concepts in the development of platinum antitumor drugs Curr Med Chem Anti-Canc Agents. 2 539 551
12. N. J. Moreland M. Illand Y. T. Kim J. Paul R. Brown 1999 Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin Cancer Res. 59 2102 2106
13. Z. H. Siddik 2003 Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene. 22 7265 7279
14. F. M. Muggia G. Los 1993 Platinum resistance: laboratory findings and clinical implications Stem Cells. 11 182 193
15. A. de Graeff R. J. Slebos S. Rodenhuis 1988 Resistance to cisplatin and analogues: mechanisms and potential clinical implications Cancer Chemother Pharmacol. 22 325 332
16. M. J. McKeage 2005 New-generation platinum drugs in the treatment of cisplatin-resistant cancers Expert Opin Investig Drugs. 14 1033 1046
17. G. Biagini A. Pugnaloni A. Damadei A. Bertani A. Belligolli V. Bicchiega R. Muzzarelli 1991 Morphological study of the capsular organization around tissue expanders coated with N-carboxybutyl chitosan Biomaterials. 12 287 291
18. J. S. Pieper P. B. van Wachem M. J. A. van Luyn L. A. Brouwer T. Hafmans J. H. Veerkamp T. H. van Kuppevelt 2000 Attachment of glycosaminoglycans to collagenous matrices modulates the tissue response in rats Biomaterials. 21 1689 1699
19. M. Prabaharan J. F. Mano 2005 Chitosan-based particles as controlled drug delivery systems Drug Deliv. 12 41 57
20. A. Polykratis P. Katsoris J. Courty E. Papadimitriou 2005 Characterization of heparin affin regulatory peptide signaling in human endothelial cells J Biol Chem. 280 22454 22461
21. M. K. Chourasia S. K. Jain 2004 Polysaccharides for colon targeted drug delivery Drug Deliv. 11 129 148
22. V. R. Sinha R. Kumria 2001 Polysaccharides in colon-specific drug delivery Int J Pharm. 224 19 38
23. C. Haase R. Bergmann F. Fuechtner A. Hoepping J. Pietzsch 2007 l-type amino acid transporters LAT1 and LAT4 in cancer: uptake of 3-O-methyl-6-18F- fluoro-l-dopa in human adenocarcinoma and squamous cell carcinoma in vitro and in vivo J Nucl Med. 48 2063 2071
24. C. Li J. E. Price L. Milas N. R. Hunter S. Ke D. F. Yu C. Charnsangavej S. Wallace 1999 Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors Clin Cancer Res. 5 891 897
25. Y. Sedletska M. J. Giraud-Panis J. M. Malinge 2005 Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways Curr Med Chem Anticancer Agents. 5 251 265
26. S. Fulda M. Los C. Friesen K.M. Debatin 1998 Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system Int J Cancer. 76 105 114
27. H. Kojima K. Endo H. Moriyama Y. Tanaka E. S. Alnemri C. A. Slapak B. Teicher D. Kufe R. Datta 1998 Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance J Biol Chem. 273 16647 16650
28. K. M. Henkels J. J. Turchi 1999 Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines Cancer Res. 59 3077 3083
29. G. D. Diaz Q. Li R. H. Dashwood 2003 Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin Cancer Res. 63 1254 1261
30. B. S. Cummings G. R. Kinsey L. J. Bolchoz R. G. Schnellmann 2004 Identification of caspase-independent apoptosis in epithelial and cancer cells J Pharmacol Exp Ther. 310 126 134
31. R. E. Aird J. Cummings A. A. Ritchie M. Muir R. E. Morris H. Chen P. J. Sadler D. I. Jodrell 2002 In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer Br J Cancer. 86 1652 1657
32. V. V. Ogryzko P. Wong B. H. Howard 1997 WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases Mol Cell Biol. 17 4877 4882
33. V. Gottifredi K. McKinney M. V. Poyurovsky C. Prives 2004 Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block J Biol Chem. 279 5802 5810
34. A. L. Gartel A. L. Tyner 1999 Transcriptional regulation of the p21((WAF1/CIP1)) gene Exp Cell Res. 246 280 289
35. S. Gilfillan E. L. Ho M. Cella W. M. Yokoyama M. Colonna 2002 NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation Nat Immunol. 3 1150 1155